The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines.
The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence.
Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa.
Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/).
This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.
European urology. 2024 Apr 29 [Epub ahead of print]
Derya Tilki, Roderick C N van den Bergh, Erik Briers, Thomas Van den Broeck, Oliver Brunckhorst, Julie Darraugh, Daniel Eberli, Gert De Meerleer, Maria De Santis, Andrea Farolfi, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Ann M Henry, Michael Lardas, Geert J L H van Leenders, Matthew Liew, Estefania Linares Espinos, Jan Oldenburg, Inge M van Oort, Daniela E Oprea-Lager, Guillaume Ploussard, Matthew J Roberts, Olivier Rouvière, Ivo G Schoots, Natasha Schouten, Emma J Smith, Johan Stranne, Thomas Wiegel, Peter-Paul M Willemse, Philip Cornford
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address: ., Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., Patient advocate, Hasselt, Belgium., Department of Urology, University Hospitals Leuven, Leuven, Belgium., Department of Urology, King's College London, London, UK., European Association of Urology, Arnhem, The Netherlands., Department of Urology, University Hospital Zurich, Zurich, Switzerland., Department of Radiation Oncology, University Hospital Leuven, Leuven, Belgium., Department of Urology, Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria., Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland., Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK., Department of Urology, Metropolitan General Hospital, Athens, Greece., Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK., Department of Urology, University Hospital La Paz, Madrid, Spain., Akershus University Hospital, Lørenskog, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway., Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands., Department of Urology, La Croix du Sud Hospital, Toulouse, France., Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland Centre for Clinical Research, Herston, Australia., Department of Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Lyon 1, UFR Lyon-Est, Lyon, France., Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital-Västra Götaland, Gothenburg, Sweden., Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany., Department of Urology, Cancer Center University Medical Center Utrecht, Utrecht, The Netherlands.